New combo targets hard-to-treat breast cancer in early trial

NCT ID NCT05128734

Not yet recruiting Disease control Sponsor: AHS Cancer Control Alberta Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 19 times

Summary

This study tests whether a chemotherapy drug (temozolomide) works better alone or combined with another drug (olaparib) for people with a specific type of triple-negative breast cancer that has spread or cannot be removed. About 40 adults with a genetic marker called MGMT methylation will be randomly assigned to one of two treatment groups. The goal is to see how well the treatments control the cancer and how long people live without the disease getting worse.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER TRIPLE NEGATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Arthur J.E. Child Comprehensive Cancer Centre

Calgary, Alberta, T2N 5G2, Canada

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BREAST CANCER TRIPLE NEGATIVE BREAST CANCER TRIPLE NEGATIVE